MediGene Initiates Clinical Phase I/II Trial of Cancer-Killing Virus NV1020 for the Treatment of Liver Metastases MARTINSRIED, Germany and SAN...
3-Months Report: MediGene AG Reduces Net Loss by 84% - Fivefold increase in revenues from 0.7 million euro to 3.9 million euro MARTINSRIED...
MediGene's First Drug Eligard(R) Is Launched * Marketing partner Yamanouchi launched cancer drug Eligard(R) in Germany today. MARTINSRIED, Germany...
MediGene Initiates Phase 2 Clinical Trial of Polyphenon(R) E Ointment for the Treatment of Actinic Keratosis on Schedule Expanding Market...
MediGene Decides on Extension of Clinical Development of Polyphenon(R) E Ointment to Additional Tumor Disease: Phase 2 Trial for Actinic Keratosis...
MediGene to Hold Conference Call to Discuss Excellent Clinical Results Of the Polyphenon(R) E Ointment European Phase 3 Trial MARTINSRIED...
MediGene Achieves Excellent Clinical Results With Polyphenon(R) E Ointment in European Phase 3 Trial * Data indicate high and lasting efficacy as...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.